Indication
KRAS G12R
3 clinical trials
2 products
Product
ELI-002Clinical trial
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer Based on NGS Test Results in Hunan Province, ChinaStatus: Recruiting, Estimated PCD: 2026-12-31
Product
Chemotherapy.